arrow

From NeuroLex

Jump to: navigation, search



Alemtuzumab

Name: Alemtuzumab
Description: Humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Pharmacology: Campath is used to treat leukemia by exploiting antibody mediated lysis of CD52 presenting cells. The CD52 antigen is a cell surface protein found on essentially all B and T lymphocytes, a majority of monocytes, macrophages and most granulocytes. The CD52 antigen is not present on erythrocytes or hematopoetic stem cells. In leukemia there is an excess of B and T cells, so Campath permits selective reduction of lymphocyte populations. Mechanism of action: Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells. Drug type: Approved. Biotech. Investigational. Drug category: Antineoplastic Agents
Synonym(s): alemtuzumab, Campath, Campath (ILEX Pharmaceuticals LP), MabCampath
Has role: Drug
Super-category: Molecular entity
URL: http://www.drugbank.ca/drugs/DB00087
Id: DB00087
Related to: CAMPATH-1 antigen, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c
Link to OWL / RDF: Download this content as OWL/RDF


Contributors

Ccdbuser, Nifbot2



bookmark
Facts about AlemtuzumabRDF feed
Commenttaken from DrugBank
CuratorAb  +
DefiningCitationhttp://www.drugbank.ca/drugs/DB00087  +
DefinitionHumanized monoclonal antibody specific to Humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Pharmacology: Campath is used to treat leukemia by exploiting antibody mediated lysis of CD52 presenting cells. The CD52 antigen is a cell surface protein found on essentially all B and T lymphocytes, a majority of monocytes, macrophages and most granulocytes. The CD52 antigen is not present on erythrocytes or hematopoetic stem cells. In leukemia there is an excess of B and T cells, so Campath permits selective reduction of lymphocyte populations. Mechanism of action: Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells. Drug type: Approved. Biotech. Investigational. Drug category: Antineoplastic Agents onal. Drug category: Antineoplastic Agents
Has roleDrug  +
IdDB00087  +
LabelAlemtuzumab  +
ModifiedDate14 April 2014  +
RelatedToCAMPATH-1 antigen  +, High affinity immunoglobulin gamma Fc receptor I  +, Low affinity immunoglobulin gamma Fc region receptor III-B  +, Complement C1r subcomponent  +, Complement C1q subcomponent subunit A  +, Complement C1q subcomponent subunit B  +, Complement C1q subcomponent subunit C  +, Low affinity immunoglobulin gamma Fc region receptor III-A  +, Low affinity immunoglobulin gamma Fc region receptor II-a  +, Low affinity immunoglobulin gamma Fc region receptor II-b  +, and Low affinity immunoglobulin gamma Fc region receptor II-c  +
SuperCategoryMolecular entity  +
Synonymalemtuzumab  +, Campath  +, Campath (ILEX Pharmaceuticals LP)  +, and MabCampath  +